



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 18 Mar 2019 (#9)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Contact: RGMO Pre-Awards [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)

## Important Notices & News

**The MRC-NIH Funding Opportunity Announcements (FOA's) are published!** See FOA 1 to 4. Make sure that you choose the correct FOA:

- Research areas supported under R01 ([RFA-AI-19-022](#)) and U01 ([RFA-AI-19-023](#)) include HIV/AIDS and HIV/AIDS-associated malignancies.
- Research areas supported under R01 ([RFA-AI-19-024](#)) U01 ([RFA-AI-19-025](#)) include tuberculosis; sexually transmitted infections; parasitic infections; arboviruses and emerging/re-emerging viral pathogens; and vector biology and control.
- U01 applications will be a partnership with eligible NIH Intramural Research Program (IRP) investigators conducting research within the laboratories and clinics of the NIH.
- Applications must include at least one PD/PI affiliated with the U.S. institution and a South African PD/PI
- The FOA's encourage
  - Collaboration with underrepresented scientists, defined as individuals from African, Coloured and Indian population groups in South Africa.
  - Applications from New Investigators and Early Stage Investigators (<https://grants.nih.gov/policy/early-investigators/index.htm>)
  - Applicants to engage investigators from Kenya, Lesotho, Uganda, and Zimbabwe as collaborators.

### 1. U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (HIV/AIDS) (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-19-022](#)

**Type:** R01

**Application Due Date:** July 26, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to continue the U.S.-South Africa Program for Collaborative Biomedical Research into Phase 2. Research areas supported under this program include HIV/AIDS and HIV/AIDS-associated malignancies. Applications must include at least one PD/PI affiliated with the U.S. institution and a South African PD/PI from an eligible institution from South Africa. This FOA encourages collaboration with underrepresented scientists in South Africa. Underrepresented scientists are defined as individuals from African, Coloured and Indian population groups in South Africa. This FOA encourages New Investigators and Early Stage Investigators (<https://grants.nih.gov/policy/early-investigators/index.htm>) from the U.S. and South Africa to participate in this research program. Finally, to stimulate regional excellence in scientific research, Phase 2 of the U.S.-South Africa Program for Collaborative Biomedical Research encourages applicants to engage investigators from Kenya, Lesotho, Uganda, and Zimbabwe as collaborators.

**Budget:** For this specific FOA, the issuing IC and partner components intend to commit an estimated total of \$3.3 million to fund 8-10 awards in FY 2020. Application budgets are limited to \$350,000 in total costs.

## 2. U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (HIV/AIDS) (U01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-AI-19-023\)](#)

**Type:** U01

**Application Due Date:** July 26, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to continue the U.S.-South Africa Program for Collaborative Biomedical Research into Phase 2. Research areas supported under this program include HIV/AIDS and HIV/AIDS-associated malignancies. This opportunity is specifically designed to promote partnerships between eligible NIH Intramural Research Program (IRP) investigators conducting research within the laboratories and clinics of the NIH and eligible South African investigators (e.g., those conducting research in eligible laboratories in South Africa). In order to be eligible for this program, the application must include at least one NIH IRP investigator serving as a Project Scientist with an equal role in the conceptualization, design and execution of the research. An overarching goal of this bilateral program is to engage underrepresented groups of scientists in South Africa and historically disadvantaged institutions. This FOA encourages collaboration with underrepresented scientists within South Africa. Underrepresented scientists are defined as individuals from African, Coloured and Indian population groups in South Africa. This FOA encourages New Investigators and Early Stage Investigators (<https://grants.nih.gov/policy/early-investigators/index.htm>) from the U.S. and South Africa to participate in this research program. Finally, to stimulate regional excellence in scientific research, Phase 2 of the U.S.-South Africa Program for Collaborative Biomedical Research encourages applicants to engage investigators from Kenya, Lesotho, Uganda, and Zimbabwe as collaborators. Applications proposing the topics below will be considered non-responsive and will not be reviewed:

- Stage III or IV clinical trials.
- Research using select agents.
- Applications without the appropriate PD/PI requirements

**Budget:** For this FOA, Issuing IC and partner components intend to commit up to \$3.0 million to fund 8-10 awards in FY 2020. Application budgets are limited to \$250,000 in total costs. The NIH IRP investigator's costs will not be included in the award issued to the recipient. The maximum project period is 5 years

## 3. U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (Infectious Diseases) (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-AI-19-024\)](#)

**Type:** R01

**Application Due Date:** July 26, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to continue the U.S.-South Africa Program for Collaborative Biomedical Research into Phase 2. Research areas supported under this program include: tuberculosis; sexually transmitted infections; parasitic infections; arboviruses and emerging/re-emerging viral pathogens; and vector biology and control. The intent of this FOA is to foster, stimulate, and/or expand basic, translational, behavioral and applied research that will advance scientific discovery and engage U.S. and South African scientists working collaboratively in the areas of infectious disease research. Applications must include at least one PD/PI affiliated with the U.S. institution and a South African PD/PI from an eligible institution from South Africa. The South African PDs/Pis must be either permanently employed at an eligible South African research institution or be in a long-term contract (at least for the minimum of the duration of the project). Postgraduate students, full or part-time, are not eligible to serve as PDs/Pis. This FOA encourages collaboration with underrepresented scientists in South Africa.

Underrepresented scientists are defined as individuals from African, Coloured and Indian population groups in South Africa. This FOA encourages New Investigators and Early Stage Investigators (<https://grants.nih.gov/policy/early-investigators/index.htm>) and encourages applicants to engage investigators from Kenya, Lesotho, Uganda, and Zimbabwe as collaborators

**Budget:** NIAID intends to commit up to \$1.0 million to fund 2-3 awards in FY 2020. Application budgets are limited to \$350,000 in total costs. The maximum project period is 5 years.

## 4. U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (Infectious Diseases) (U01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-AI-19-025\)](#)

**Type:** U01

**Application Due Date:** July 26, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to continue the U.S.-South Africa Program for Collaborative Biomedical Research into Phase 2. Research areas supported under this program include tuberculosis; sexually transmitted infections; parasitic infections; arboviruses and emerging/re-emerging viral pathogens; and vector biology and control. This opportunity is designed to promote partnerships between eligible NIH Intramural Research Program (IRP) investigators (e.g. those conducting research within the laboratories and clinics of the NIH) and eligible South African investigators (e.g., those conducting research in eligible laboratories in South Africa). In order to be eligible for this program, the application must include at least one NIH IRP investigator serving as a Project Scientist with an equal role in the conceptualization, design and execution of the research. The intent of this FOA is to foster, stimulate, and/or expand basic, translational, behavioral and applied research that will advance scientific discovery.

An overarching goal of this bilateral program is to engage underrepresented groups of scientists in South Africa and historically disadvantaged institutions. This FOA encourages New Investigators and Early Stage Investigators (<https://grants.nih.gov/policy/early-investigators/index.htm>). Finally, to stimulate regional excellence in scientific research, Phase 2 of the U.S.-South Africa Program for Collaborative Biomedical Research encourages applicants to engage investigators from Kenya, Lesotho, Uganda, and Zimbabwe as collaborators in the research project. One of the South African PDs/Pis must serve as the contact PD/PI and an eligible South African Institution must be the applicant institution. The South African PDs/Pis must be either permanently employed at an eligible South African research institution or be in a long-term contract (at least for the minimum of the duration of the project). Postgraduate students, full or part-time, are not eligible to serve as PDs/Pis.

**Budget:** For this specific FOA, NIAID intends to commit up to \$1.0 million to fund 3-4 awards in FY 2020. Application budgets are limited to \$250,000 in total costs. The NIH IRP investigator's costs will not be included in the award issued to the recipient. The maximum project period is 5 years.